

## DAFTAR PUSTAKA

- Abdel-Magid, A. F. (2017) 'Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers', *ACS Medicinal Chemistry Letters*. doi: 10.1021/acsmmedchemlett.7b00426.
- Adamo, A. *et al.* (2011) 'LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells', *Nature Cell Biology*. doi: 10.1038/ncb2246.
- Andreassen, B. K. *et al.* (2016) 'Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014', *BMC Cancer*. doi: 10.1186/s12885-016-2832-x.
- Binda, C. *et al.* (2010) 'Biochemical, structural, and biological evaluation of tranylecypramine derivatives as inhibitors of histone demethylases LSD1 and LSD2', *Journal of the American Chemical Society*. doi: 10.1021/ja101557k.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*. doi: 10.3322/caac.21492.
- Carneiro, B. A. *et al.* (2015) 'Emerging therapeutic targets in bladder cancer', *Cancer Treatment Reviews*. doi: 10.1016/j.ctrv.2014.11.003.
- Chan, K. S. *et al.* (2009) 'Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells', *Proceedings of the National Academy of Sciences of the United States of America*. doi: 10.1073/pnas.0906549106.
- Cheung, P. and Lau, P. (2005) 'Epigenetic regulation by histone methylation and histone variants', *Molecular Endocrinology*. doi: 10.1210/me.2004-0496.
- Chou, R. *et al.* (2015) 'Urinary biomarkers for diagnosis of bladder cancer: A systematic review and meta-analysis', *Annals of Internal Medicine*. doi: 10.7326/M15-0997.
- Cumberbatch, M. G. K. *et al.* (2018) 'Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018', *European Urology*. European Association of Urology, 74(6), pp. 784–795. doi: 10.1016/j.eururo.2018.09.001.
- Fu, X., Zhang, P. and Yu, B. (2017) 'Advances toward LSD1 inhibitors for cancer therapy', *Future Medicinal Chemistry*. doi: 10.4155/fmc-2017-0068.
- Ghosh, M. *et al.* (2014) 'Targeted therapies in urothelial carcinoma', *Current Opinion in Oncology*. doi: 10.1097/CCO.0000000000000064.
- Hayami, S. *et al.* (2011) 'Overexpression of LSD1 contributes to human

carcinogenesis through chromatin regulation in various cancers', *International Journal of Cancer*. doi: 10.1002/ijc.25349.

Heemers, H. V. and Tindall, D. J. (2007) 'Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex', *Endocrine Reviews*. doi: 10.1210/er.2007-0019.

Kahl, P. *et al.* (2006) 'Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence', *Cancer Research*. doi: 10.1158/0008-5472.CAN-06-1570.

Kauffman, E. C. *et al.* (2011) 'Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer', *Molecular Carcinogenesis*. doi: 10.1002/mc.20758.

Knowles, M. A. and Hurst, C. D. (2015) 'Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity', *Nature Reviews Cancer*. doi: 10.1038/nrc3817.

Lan, W., Zhang, D. and Jiang, J. (2013) 'The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells', *Medical Hypotheses*. doi: 10.1016/j.mehy.2013.09.005.

Ligr, M. *et al.* (2010) 'Tumor suppressor function of androgen receptor coactivator ARA70 $\alpha$  in prostate cancer', *American Journal of Pathology*. doi: 10.2353/ajpath.2010.090293.

Lombard, A. P. and Mudryj, M. (2015) 'The emerging role of the androgen receptor in bladder cancer', *Endocrine-Related Cancer*. doi: 10.1530/ERC-15-0209.

Magliulo, D., Bernardi, R. and Messina, S. (2018) 'Lysine-specific demethylase 1A as a promising target in acute myeloid leukemia', *Frontiers in Oncology*. doi: 10.3389/fonc.2018.00255.

Metzger, E. *et al.* (2005) 'LSD1 demethylates repressive histone marks to promote androgen-receptor- dependent transcription', *Nature*. doi: 10.1038/nature04020.

Mizushima, T., Tirador, K. A. and Miyamoto, H. (2017) 'Androgen receptor activation: a prospective therapeutic target for bladder cancer?', *Expert Opinion on Therapeutic Targets*. doi: 10.1080/14728222.2017.1280468.

Perillo, B. *et al.* (2008) 'DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression', *Science*. doi: 10.1126/science.1147674.

Ploeg, M., Aben, K. K. H. and Kiemeny, L. A. (2009) 'The present and future burden of urinary bladder cancer in the world', *World Journal of Urology*, 27(3), pp. 289–293. doi: 10.1007/s00345-009-0383-3.

- Rose, N. R. *et al.* (2010) 'Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches', *Journal of Medicinal Chemistry*. doi: 10.1021/jm901680b.
- Saginala, K. *et al.* (2020) 'Epidemiology of Bladder Cancer', pp. 1–12. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151633/>.
- Schatz, P. (2020) *Gross Anatomy of Urine Transport · Anatomy and Physiology, OpenStax College, Anatomy and Physiology. OpenStax CNX.* <http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@11.1>. OpenStax College, Anatomy and Physiology. OpenStax CNX. <http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@11.1>.
- Shi, Yujiang *et al.* (2004) 'Histone demethylation mediated by the nuclear amine oxidase homolog LSD1', *Cell*. doi: 10.1016/j.cell.2004.12.012.
- Sievert, K. D. *et al.* (2009) 'Economic aspects of bladder cancer: What are the benefits and costs?', *World Journal of Urology*. doi: 10.1007/s00345-009-0395-z.
- Sikic, D. *et al.* (2017) 'High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer', *Translational Oncology*. doi: 10.1016/j.tranon.2017.01.013.
- Smith, N. D. *et al.* (2016) 'Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors', *Journal of Urology*. doi: 10.1016/j.juro.2015.07.091.
- Westhoff, E. *et al.* (2016) 'Low awareness of risk factors among bladder cancer survivors: New evidence and a literature overview', *European Journal of Cancer*. Elsevier Ltd, 60, pp. 136–145. doi: 10.1016/j.ejca.2016.03.071.
- Wissmann, M. *et al.* (2007) 'Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression', *Nature Cell Biology*. doi: 10.1038/ncb1546.
- Xie, Q. *et al.* (2020) 'LSD1 Promotes Bladder Cancer Progression by Upregulating LEF1 and Enhancing EMT', *Frontiers in Oncology*. doi: 10.3389/fonc.2020.01234.
- Zheng, Y. C. *et al.* (2016) 'TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy', *Epigenomics*. doi: 10.2217/epi-2015-0002.
- Zhou, M. *et al.* (2017) 'Protocol for the Examination of Specimens From Patients With Carcinoma of the Urinary Bladder', (June), pp. 1–18.